Physician profile
Michael A Reddix
NPI 1437163854
$2,455.66
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $697 · 2021: $519 · 2022: $283 · 2023: $323 · 2024: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $506.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $439.86 | 2019-2023 | Breztri, Farxiga |
| Novo Nordisk INC | $331.39 | 2019-2024 | Ozempic, Rybelsus |
| Amgen INC. | $241.74 | 2019-2022 | |
| Lilly USA, LLC | $218.80 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $180.96 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.17 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $138.20 | 2020-2023 | Steglujan, Steglatro, Belsomra |
| Abbott Laboratories | $106.51 | 2022-2023 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $106.01 | 2019 | |
| Sanofi-Aventis U.S. LLC | $85.72 | 2021-2023 | |
| Abbvie INC. | $75.22 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $59.26 | 2019-2024 | |
| Astellas Pharma US INC | $56.72 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $51.89 | 2019-2020 | |
| Allergan, INC. | $48.70 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $36.34 | 2024 | Gemtesa |
| Janssen Pharmaceuticals, INC | $35.31 | 2020-2021 | |
| Lundbeck LLC | $29.25 | 2023 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $18.98 | 2022 | |
| Glaxosmithkline, LLC. | $18.28 | 2024 | Trelegy Ellipta |
| Circassia INC. | $16.64 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Reddix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.